MiRNA Sequencing and Assay Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 10.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
MiRNA Sequencing and Assay Market Analysis
The miRNA sequencing and assay market is expected to register a CAGR of 10.9% during the forecast period.
- The COVID-19 pandemic significantly impacted healthcare systems worldwide, leading to disruptions in usual care and exposing vulnerable cancer patients to increased risks. While vaccines have been approved to combat SARS-CoV-2 infection, miRNAs have emerged as a potential alternative. These miRNAs can detect SARS-CoV-2 infection by binding to its genome and limiting its post-transcriptional expression, thereby reducing the severity of COVID-19 disease.
- Notably, miR-21-3p has demonstrated the strongest binding affinity to the human coronavirus genome. With the rising number of COVID-19 cases, there is increasing demand for effective treatments, including next-generation sequencing technologies and miRNA sequencing.
- In addition to their potential in COVID-19 pathogenesis, miRNAs are critical in assessing the development, progression, prognosis, diagnosis, and treatment response in cancer patients. Some miRNAs function as tumor suppressors, while others act as oncogenes. For example, miR-451 has been identified as a potential prognostic factor in head and neck squamous cell carcinomas (HNSCCs) through miRNA profiling. The clusters of miR-375 and miR-106b-25 are implicated in the development and progression of HNSCCs. Furthermore, miRNAs have shown promise in forensic medicine due to their stability and specificity, making them useful for degraded samples or complex mixes.
- Investments in genomics have increased in recent years, with companies such as Ultima Genomics and Deep Genomics receiving significant funding for their sequencing and AI discovery platforms. Despite this growth, the market for miRNA sequencing may be hindered by a lack of expertise and computing infrastructure.
- Overall, the market for miRNA sequencing is expected to witness strong growth due to the increasing demand for effective COVID-19 treatments and the critical role of miRNAs in cancer diagnosis and treatment. However, addressing the challenges related to expertise and computing infrastructure will be crucial for sustaining this growth.
MiRNA Sequencing and Assay Market Trends
Library Preparation Kits are Expected to Hold the Largest Market Share in the miRNA Sequencing and Assay Market
- The growth of the library preparation kits segment is driven by two main factors: the capacity of these kits to shorten the RNA fragmentation process and an increase in research activities related to complex life sciences processes. Furthermore, the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and rare diseases is driving the demand for effective treatment options, propelling the growth of the miRNA market. The adoption and advancement of next-generation sequencing methods and their applications in various fields are also contributing to the growth of the miRNA sequencing market in the forecast period.
- For example, Qiagen's QIAseq miRNA Library Kit is an advanced kit that includes gel-free miRNA sequencing library preparation from 1 ng of total RNA. The kit eliminates adapter dimers and undesired RNA species to ensure the most fidelity and effective data. It incorporates Unique Molecular Indices (UMIs) for quantitatively measuring individual miRNA molecules and connects directly to the RNA-seq analysis portal for human, mouse, and rat samples. The availability of such advanced kits in the market is expected to drive the segment's growth over the forecast period.
- According to the American Cancer Society, an estimated 36,000 new cancer cases occurred in Wisconsin in 2021. Additionally, Rare Disease Day reports that rare diseases affected nearly 3.5%-5.9% of the global population in 2020, with over 300 million people living with one or more of over 6,000 identified rare diseases worldwide. With the increasing number of cancer cases, the use of library preparation kits is also increasing, which is further propelling the segment's growth.
North America Dominates the Market and Expected to do Same in the Forecast Period
- The market for miRNA sequencing and assays in the North American region is expected to experience significant growth during the forecast period. This growth can be attributed to several factors, including an increased incidence of cancer, rising demand for next-generation sequencing (NGS) and miRNA sequencing services, applications in drug development, and the adoption of the latest miRNA sequencing technology.
- Furthermore, the presence of key players such as Illumina Inc., Thermo Fisher Scientific, and others, along with increased research and development spending by companies to develop innovative and advanced products in the United States, is expected to drive regional growth.
- According to the American Cancer Society, over 1.9 million new cancer cases are expected to be diagnosed in the United States in 2023, and over 609,820 deaths are estimated to occur from cancer. This high incidence and mortality rate associated with cancer increases the demand for precision medicines and treatments for patients, subsequently increasing the demand for miRNA sequencing and assay techniques and driving the market.
- In February 2022, researchers at the University of Illinois Urbana developed a new miRNA point-of-care test for cancer detection. The test uses nanoparticles to capture tumor-specific microRNAs in human serum. Similarly, in March 2021, DiamiR agreed to acquire a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory in New Haven, Connecticut, from Interpace Biosciences. This acquisition will enhance DiamiR's capabilities to develop and commercialize its microRNA-based tests for early detection, differential diagnosis, prediction of progression, and monitoring brain health and other conditions.
- Therefore, due to the aforementioned factors, the miRNA sequencing and assay market will experience significant growth in the North American region.
MiRNA Sequencing and Assay Industry Overview
The miRNA sequencing and assay market is moderately competitive and consists of several key players. Currently, a few major players are dominating the market in terms of market share, while others are actively making acquisitions and launching new products to strengthen their market positions globally. Among the leading companies in the market are Illumina, Inc., Thermo Fisher Scientific, Qiagen N.V., Perkinelmer, Inc., and Takara Bio, Inc. These companies have a strong presence in the market and offer a wide range of miRNA sequencing and assay products to meet the needs of their customers.
MiRNA Sequencing and Assay Market Leaders
-
Illumina, Inc.
-
Thermo Fisher Scientific
-
Qiagen N.V.
-
Perkinelmer, Inc.
-
Takara Bio, Inc.
*Disclaimer: Major Players sorted in no particular order
MiRNA Sequencing and Assay Market News
- April 2022: HTC Molecular Diagnostics Inc. unveiled new features of its proprietary HTG EdgeSeq technology. The company has improved its technology, and now its new sample preparation harmonization enables miRNA and mRNA profiling without the need for additional samples.
- January 2022: Allogene Therapeutics announced a collaboration with Antion Biosciences to advance multiplex gene silencing for the development of next-generation allogeneic CAR T products. As part of the collaboration, Antion's miRNA technology (miCAR) will be used as an additional tool to enhance the efficacy and safety of allogeneic CAR T therapies.
MiRNA Sequencing and Assay Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 MiRNA Sequencing and Assay Sequencing Supremacy Over Other Methods
- 4.2.2 Increased Research in the Field of Genomics
- 4.2.3 Reduced Sequencing Costs
-
4.3 Market Restraints
- 4.3.1 Paucity of Expert and Need for Computing Infrastructure
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size - Value in USD million)
-
5.1 By Product
- 5.1.1 Sequencing Consumables
- 5.1.2 Library Preparation Kits
-
5.2 By Technology
- 5.2.1 Sequencing by Synthesis
- 5.2.2 Ion Semiconductor
- 5.2.3 SOLiD
- 5.2.4 Nanopore Sequencing
-
5.3 By End-User
- 5.3.1 Clinical Laboratory
- 5.3.2 Life Science Organization
- 5.3.3 Other End-Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Illumina, Inc.
- 6.1.2 Thermo Fisher Scientific
- 6.1.3 Qiagen N.V.
- 6.1.4 PerkinElmer, Inc.
- 6.1.5 Takara Bio, Inc.
- 6.1.6 New England Biolabs, Inc.
- 6.1.7 Norgen Biotek Corporation
- 6.1.8 Trilink Biotechnologies
- 6.1.9 Lexogen
- 6.1.10 Oxford Nanopore Technologies
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityMiRNA Sequencing and Assay Industry Segmentation
miRNA sequencing is a type of RNA-seq that uses next-generation sequencing or massively parallel sequencing of high-throughput DNA to pattern microRNAs. The substance used during the method of decoding miRNA; this sequencing is a bit different from RNA sequencing.
The miRNA sequencing and assay market is segmented by product (sequencing consumables and library preparation kits), technology (sequencing by synthesis, ion semiconductor, solid, nanopore sequencing), end user (clinical laboratory, life science organization, others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD million) for the above segments.
| By Product | Sequencing Consumables | |
| Library Preparation Kits | ||
| By Technology | Sequencing by Synthesis | |
| Ion Semiconductor | ||
| SOLiD | ||
| Nanopore Sequencing | ||
| By End-User | Clinical Laboratory | |
| Life Science Organization | ||
| Other End-Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
MiRNA Sequencing and Assay Market Research FAQs
What is the current miRNA Sequencing and Assay Market size?
The miRNA Sequencing and Assay Market is projected to register a CAGR of 10.90% during the forecast period (2024-2029)
Who are the key players in miRNA Sequencing and Assay Market?
Illumina, Inc., Thermo Fisher Scientific, Qiagen N.V., Perkinelmer, Inc. and Takara Bio, Inc. are the major companies operating in the miRNA Sequencing and Assay Market.
Which is the fastest growing region in miRNA Sequencing and Assay Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in miRNA Sequencing and Assay Market?
In 2024, the North America accounts for the largest market share in miRNA Sequencing and Assay Market.
What years does this miRNA Sequencing and Assay Market cover?
The report covers the miRNA Sequencing and Assay Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the miRNA Sequencing and Assay Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Engineering Services Outsourcing Industry Report
Statistics for the 2024 Engineering Services Outsourcing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Engineering Services Outsourcing analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
